Please use this identifier to cite or link to this item:
Title: Are current bare-metal stents still an option in selected patient populations?
Author: Leong, Kai'en
Adrianopoulos, Nick
Sharma, Anand
Noaman, Samer
Yudi, M.
Freeman, M.
Brennan, A.
Fernando, H.
Reid, C.
Clark, D.
Sebastian, M.
Ajani, A.
Duffy, S.
Oqueli, Ernesto
Issue Date: 2018
Conference Name: 66th Cardiac Society of Australia and New Zealand Annual Scientific Meeting, the International Society for Heart Research Australasian Section Annual Scientific Meeting and the 12th Annual Australia and New Zealand Endovascular Therapies Meeting.
Conference Date: August 2-5th
Conference Place: Brisbane, Queensland
Abstract: Background: Drug-eluting stents (DES) and bare-metal stents (BMS) share the same platform. Due to lower restenosis rates, DES are the standard of care. This study sought to establish if BMS outcomes were equivalent to DES in certain lesion and vessel types with inherently low risk of in-stent restenosis (ISR). Methods: A total of 4,495 patients who underwent percutaneous coronary intervention in the Melbourne Interventional Group Registry (2005–2017) with distinct BMS and DES use were analysed. Vessel size ≥2.5 mm and lesion length ≤18 mm were included. Diabetics were excluded. Follow-up and mortality outcomes were derived from National Death Index (NDI) data. Mortality hazards ratios (HR) were determined by Cox proportional hazards analysis. Results: The BMS patients were older (62.4 vs 61.5 years, p = 0.01), had more atrial fibrillation (5.8% vs 2.5%, p < 0.005), and New York Heart Association class III or IV (21.9% vs 15.2%, p < 0.005). The BMS patients more commonly had ST-elevation myocardial infarction presentation (48.4% vs 41.5%, p < 0.005) and severe heart failure (Killip class III or IV 1.4% vs 0.7%, p = 0.027). Mean follow-up was 6.8 ± 3.5 and 4.5 ± 3.6 years in BMS and DES cohorts, respectively. The NDI mortality rates were 13.2% in BMS and 6.8% in DES patients, but the multivariable adjusted-HR was not significantly different with HR = 1.20 (95% CI 0.94–1.53, p = 0.140). Conclusions: The BMS mortality rates were higher. However, BMS patients were older, with greater comorbidity and presentation acuity. Following adjustment, BMS was not an independent mortality predictor and remained relevant in selected patients, particularly those requiring truncated dual antiplatelet therapy.
Internal ID Number: 01242
Type: Conference
Appears in Collections:Research Output

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.